Movement disorders clinical practice · 2026
Effect of Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion on Parkinson's Disease-Related Pain: A 6-Month Real-World Longitudinal Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Meksi Kristi, Simonetta Clara, Ferrari Valerio, Minutilli Giovanni, Conti Matteo, Avvento Francesca, Schirinzi Tommaso, Centonze Diego, Stefani Alessandro, Pierantozzi Mariangela
Аннотация
BACKGROUND: Foslevodopa/foscarbidopa (LDp/CDp) infusion may reduce PD-related pain; however, its effects on different pain manifestations remain unclear.
OBJECTIVE: The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion.
METHODS: Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations.
RESULTS: At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged.
CONCLUSIONS: LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.
OBJECTIVE: The aim was to evaluate longitudinal changes in overall and domain-specific PD-related pain after LDp/CDp infusion.
METHODS: Twenty-six patients with advanced PD initiating LDp/CDp infusion underwent evaluation at baseline (T0) and 6 months (T1). Pain was assessed using the King's Parkinson's Disease Pain Scale (KPPS). Secondary outcomes included motor complications, quality of life (QoL), dopaminergic treatment burden, and pain-motor correlations.
RESULTS: At T1, KPPS total score decreased (9.6 ± 6.5 vs. 2.7 ± 4.7, P < 0.001), with improvements in chronic (P = 0.01), fluctuation-related (P < 0.001), and nocturnal (P < 0.001) pain. Motor complications reduced (P < 0.001), and fluctuation-related pain reduction correlated with motor complication changes (ρ = 0.46, P = 0.04). QoL improved (P = 0.006), whereas dopaminergic treatment burden was unchanged.
CONCLUSIONS: LDp/CDp infusion improved PD-related pain, particularly chronic, fluctuation-related, and nocturnal pain, with a parallel improvement in QoL, suggesting benefits beyond motor complication management.